Kinnate Biopharma Inc. vende su inhibidor Pan-RAF en fase de investigación, exarafenib, a Pierre Fabre Laboratories ...Middle East

Kinnate ha firmado un Acuerdo de Compra de Activos ("APA", por sus siglas en inglés) con Pierre Fabre Laboratories por los derechos mundiales del exarafenib y otros activos del programa pan-RAF. La operación se enmarca en la búsqueda de alternativas estratégicas anunciada anteriormente...

Hence then, the article about kinnate biopharma inc vende su inhibidor pan raf en fase de investigacion exarafenib a pierre fabre laboratories was published today ( Monday 04/03/2024 - 06:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kinnate Biopharma Inc. vende su inhibidor Pan-RAF en fase de investigación, exarafenib, a Pierre Fabre Laboratories )

Also on site :

• ‘Fire Country’ Announces Major Change After Season 4 Cast Shake-Up
• Roger Waters Calls Sharon Osbourne a ‘Raging Zionist’ in Heated TV Interview
• Melissa Gilbert Begs Court to Protect 'Sweet Husband' Timothy Busfield While in Jail